Clinical Trials Logo

Leukemia, Promyelocytic, Acute clinical trials

View clinical trials related to Leukemia, Promyelocytic, Acute.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT01869803 Approved for marketing - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia

Start date: n/a
Phase: N/A
Study type: Expanded Access

This clinical trial studies gemtuzumab ozogamicin in treating patients with relapsed or refractory acute myeloid leukemia or acute promyelocytic leukemia. Monoclonal antibodies, such as gemtuzumab ozogamicin, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them.